In this Section |
201409 Use of health services among clinic and pharmacy oral contraceptive users in El Paso, TexasWednesday, November 11, 2009: 8:30 AM
In Mexico, oral contraceptives (OCs) are available from pharmacies without a prescription, while in the US a prescription is required. The Border Contraceptive Access Study aims to understand contraceptive use among women in El Paso, Texas, who have the option to obtain OCs over-the-counter (OTC) at Mexican pharmacies or at US public clinics. In the debate regarding OTC access, some argue women will be less likely to obtain necessary preventive care if not required to visit a clinician to obtain OCs.
This analysis speaks to this debate by looking at experiences with health care visits among 533 clinic and 515 pharmacy users in El Paso. Women reported relatively low levels of a usual source of care (62% for clinic, 68% for pharmacy). The majority of clinic users (98.7%) and pharmacy users (89.4%) reported Pap screening in the past three years, and 99.6% and 96.9% reported ever having a Pap smear. In adjusted logistic regression models, clinic users and parous women had significantly higher odds of ever having Pap screening and being screened in the past 3 years (p<0.001). Clinic users and parous women also had higher adjusted odds of ever having a pelvic (p<0.01) or breast exam (p<0.001) or screening for STIs (p<0.01). Although women in El Paso who choose OTC access to OCs report statistically significant lower use of preventive care, the vast majority still obtain these services. The findings suggest that OTC access does not reduce preventive screening in a clinically significant degree.
Learning Objectives: Keywords: Contraceptives, Hispanic
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: Co-investigator on Border Contraceptive Access Study. PhD in demography/sociology with over 10 years experience studying contraceptive use. I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
See more of: Access to contraception on the US-Mexico border
See more of: Population, Reproductive and Sexual Health |